Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | TRANSCEND-CLL-004: lisocabtagene maraleucel in CLL

Tanya Siddiqi, MD, of the City of Hope National Medical Center, Duarte, CA, discusses results from the Phase I/II TRANSCEND-CLL-004 (NCT03331198) study, evaluating the safety and efficacy of the Juno CAR T-cell, lisocabtagene maraleucel, in chronic lymphocytic leukemia (CLL) patients pre-treated with a BTK inhibitor. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).